With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

China’s obesity crisis is a sizeable profit opportunity. More than half of Chinese adults are overweight or obese — a figure expected to hit two-thirds by 2030. That is nearly 900mn people, a market ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Drug compounders are moving to block the FDA’s decision that Novo Nordisk A/S’s weight loss drug is no longer in shortage, ...

Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo ...

Novo Nordisk is rolling out a new national marketing campaign for its GLP-1 juggernaut, teaming up with celebrities and other patients to show what life looks like in their “Ozempic Eras.” ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street for the second time. The pharmaceutical giant, known for its blockbuster ...

Eli Lilly says it is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP and ...

Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents ...